Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  efaproxiral
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-7 of 7 for your search:
Start Over
Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000067957, ALLOS-RSR13RT-009, NCT00005887
Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: RT-016, NCT00083304
Phase I/II Study of Efaproxiral and Carmustine in Patients With Progressive or Recurrent High-Grade Gliomas
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NABTT-9806, JHOC-NABTT-9806, NCT00005855
Phase II Study of RSR13 in Patients Receiving Cranial Radiation Therapy for Glioblastoma Multiforme
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NABTT-9707, ALLOS-RSR13RT-007, JHOC-NABTT-9707
Phase II Study of RSR-13 in Patients With Primary Breast, Non-Small Cell Lung, Genitourinary, or Gastrointestinal Carcinoma or Melanoma Receiving Standard Cranial Radiotherapy for Brain Metastases (Summary Last Modified 04/2002)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-9711049, ALLOS-RSR13RT-008, NCI-G99-1611
Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000067445, ALLOS-RSR13RT-010, VU-VCC-THO-9828, NCT00004202
Phase IB Study to Evaluate the Safety and Tolerance of Repetitive Daily Intravenous Doses of RSR-13 Administered to Patients Receiving Cranial Radiation Therapy for Glioblastoma Multiforme
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NABTT-9606, JHOC-NABTT-9606, NCI-T96-0085
Start Over